Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Depreciation & Amortization (IS)LeasesOther Gross PP&E AdjustmentsReceivables - Other
Ratios

Moleculin Biotech (MBRX) Receivables - Net (2018 - 2023)

Moleculin Biotech's Receivables - Net history spans 5 years, with the latest figure at $5000.0 for Q2 2023.

  • Quarterly results put Receivables - Net at $5000.0 for Q2 2023, changed N/A from a year ago — trailing twelve months through Jun 2023 was $5000.0 (changed N/A YoY), and the annual figure for FY2022 was $20000.0, changed.
  • Receivables - Net for Q2 2023 was $5000.0 at Moleculin Biotech, down from $20000.0 in the prior quarter.
  • In the past five years, Receivables - Net ranged from a high of $316000.0 in Q3 2019 to a low of $1000.0 in Q4 2019.
  • The 4-year median for Receivables - Net is $5000.0 (2023), against an average of $68600.0.
  • Peak annual rise in Receivables - Net hit 98.21% in 2019, while the deepest fall reached 98.21% in 2019.
  • Year by year, Receivables - Net stood at $1000.0 in 2019, then changed by 0.0% to $1000.0 in 2020, then surged by 1900.0% to $20000.0 in 2022, then tumbled by 75.0% to $5000.0 in 2023.
  • According to Business Quant data, Receivables - Net over the past three periods came in at $5000.0, $20000.0, and $1000.0 for Q2 2023, Q4 2022, and Q1 2020 respectively.